<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31500113</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>18</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Gene Therapy for ALS-A Perspective.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20184388</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease (MND) with no cure. Recent advances in gene therapy open a new perspective to treat this disorder-particularly for the characterized genetic forms. Gene therapy approaches, involving the delivery of antisense oligonucleotides into the central nervous system (CNS) are being tested in clinical trials for patients with mutations in <i>SOD1</i> or <i>C9orf72</i> genes. Viral vectors can be used to deliver therapeutic sequences to stably transduce motor neurons in the CNS. Vectors derived from adeno-associated virus (AAV), can efficiently target genes and have been tested in several pre-clinical settings with promising outcomes. Recently, the Food and Drug Administration (FDA) approved Zolgensma, an AAV-mediated treatment for another MND-the infant form of spinal muscular atrophy. Given the accelerated progress in gene therapy, it is potentially a promising avenue to develop an efficient and safe cure for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cappella</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm UMRS 974, Centre of Research in Myology (CRM), Institut de Myologie, GH Piti&#xe9; Salp&#xea;tri&#xe8;re, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciotti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm UMRS 974, Centre of Research in Myology (CRM), Institut de Myologie, GH Piti&#xe9; Salp&#xea;tri&#xe8;re, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen-Tannoudji</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm UMRS 974, Centre of Research in Myology (CRM), Institut de Myologie, GH Piti&#xe9; Salp&#xea;tri&#xe8;re, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biferi</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm UMRS 974, Centre of Research in Myology (CRM), Institut de Myologie, GH Piti&#xe9; Salp&#xea;tri&#xe8;re, 75013 Paris, France. mg.biferi@institut-myologie.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">RNA interference</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotides</Keyword><Keyword MajorTopicYN="N">lentiviral vectors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31500113</ArticleId><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pii">ijms20184388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland J.M., Barohn R.J., McVey A.L., Katz J.S., Dimachkie M.M. Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis. Neurol. Clin. 2015;33:735&#x2013;748. doi: 10.1016/j.ncl.2015.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.006</ArticleId><ArticleId IdType="pmc">PMC4629510</ArticleId><ArticleId IdType="pubmed">26515618</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710&#x2013;723. doi: 10.1038/nrn1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogden A., Foley G., Henderson R.D., James N., Aoun S.M. Amyotrophic lateral sclerosis: Improving care with a multidisciplinary approach. J. Multidiscip. Healthc. 2017;10:205&#x2013;215. doi: 10.2147/JMDH.S134992.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S134992</ArticleId><ArticleId IdType="pmc">PMC5446964</ArticleId><ArticleId IdType="pubmed">28579792</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9 doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosolini A.P., Sleigh J.N. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2017;10 doi: 10.3389/fnmol.2017.00405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00405</ArticleId><ArticleId IdType="pmc">PMC5725447</ArticleId><ArticleId IdType="pubmed">29270111</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clinic. Investig. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Gao G. State-of-the-art human gene therapy: Part II. Gene therapy strategies and applications. Discov. Med. 2014;18:151&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440458</ArticleId><ArticleId IdType="pubmed">25227756</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyenvalle A. Gene and splicing therapies for neuromuscular diseases. Front. Biosci. 2015;20:1190&#x2013;1233. doi: 10.2741/4367.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4367</ArticleId><ArticleId IdType="pubmed">25961553</ArticleId></ArticleIdList></Reference><Reference><Citation>Choong C.-J., Baba K., Mochizuki H. Gene therapy for neurological disorders. Expert Opin. Biol. Ther. 2016;16:143&#x2013;159. doi: 10.1517/14712598.2016.1114096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2016.1114096</ArticleId><ArticleId IdType="pubmed">26642082</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Gao G. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov. Med. 2014;18:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440413</ArticleId><ArticleId IdType="pubmed">25091489</ArticleId></ArticleIdList></Reference><Reference><Citation>Durymanov M., Reineke J. Non-viral Delivery of Nucleic Acids: Insight into Mechanisms of Overcoming Intracellular Barriers. Front. Pharmacol. 2018;9 doi: 10.3389/fphar.2018.00971.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00971</ArticleId><ArticleId IdType="pmc">PMC6111240</ArticleId><ArticleId IdType="pubmed">30186185</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch K.M., Miller T.M. Antisense oligonucleotides: Translation from mouse models to human neurodegenerative diseases. Neuron. 2017;94:1056&#x2013;1070. doi: 10.1016/j.neuron.2017.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.010</ArticleId><ArticleId IdType="pmc">PMC5821515</ArticleId><ArticleId IdType="pubmed">28641106</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. Method. Clin. Dev. 2017;8:87&#x2013;104. doi: 10.1016/j.omtm.2017.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5758940</ArticleId><ArticleId IdType="pubmed">29326962</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangi G., Traynor B.J. Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 2015;1607:75&#x2013;93. doi: 10.1016/j.brainres.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.10.009</ArticleId><ArticleId IdType="pmc">PMC5916786</ArticleId><ArticleId IdType="pubmed">25316630</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.-M., Masson G.L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G., Traynor B.J., Hardiman O., Chi&#xf2; A., Mitchell D., Swingler R.J., Millul A., Benn E., Beghi E. Incidence of Amyotrophic Lateral Sclerosis in Europe. J. Neurol. Neurosurg. Psychiatr. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Deenen J.C.W., Horlings C.G.C., Verschuuren J.J., Verbeek A.L.M., Engelen B.G.M. van The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. J. Neuromuscul. Dis. 2015;2:73&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">28198707</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A., Logroscino G., Jick S.S., Hern&#xe1;n M.A. Incidence and lifetime risk of motor neuron disease in the United Kingdom: A population-based study. Eur. J. Neurol. 2009;16:745&#x2013;751. doi: 10.1111/j.1468-1331.2009.02586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02586.x</ArticleId><ArticleId IdType="pmc">PMC3093130</ArticleId><ArticleId IdType="pubmed">19475756</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G., Piccininni M. Amyotrophic Lateral Sclerosis Descriptive Epidemiology: The Origin of Geographic Difference. NED. 2019;52:93&#x2013;103. doi: 10.1159/000493386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493386</ArticleId><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B.G. Prognostic factors in ALS: A critical review. Amyotroph. Lateral. Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimoto M., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral. Scler. Frontotemporal Degener. 2014;15:610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Wate R., Zhang J., Ohnishi S., Kaneko S., Ito H., Nakano S., Kusaka H. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 2008;213:448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS) J. Neurol. Sci. 2010;288:1&#x2013;12. doi: 10.1016/j.jns.2009.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2009.09.029</ArticleId><ArticleId IdType="pubmed">19840884</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A., Lattante S., Zollino M., Marangi G., Luigetti M., Del Grande A., Servidei S., Trombetta F., Sabatelli M. P525L FUS mutation is consistently associated with a severe form of juvenile Amyotrophic Lateral Sclerosis. Neuromuscul. Disord. 2012;22:73&#x2013;75. doi: 10.1016/j.nmd.2011.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2011.08.003</ArticleId><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Hentati A., Tainer J.A., Iqbal Z., Cayabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261:1047&#x2013;1051. doi: 10.1126/science.8351519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.-F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001;2:806&#x2013;819. doi: 10.1038/35097565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854. doi: 10.1126/science.281.5384.1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5384.1851</ArticleId><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler A.R., Donnelly C.J., Rothstein J.D. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 2016;17:383&#x2013;395. doi: 10.1038/nrn.2016.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.38</ArticleId><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A.M. C9orf72 -mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., MacNair L., McGoldrick P., McKeever P.M., McLean J.R., Zhang M., Keith J., Zinman L., Rogaeva E., Robertson J. Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann. Neurol. 2015;78:568&#x2013;583. doi: 10.1002/ana.24469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24469</ArticleId><ArticleId IdType="pubmed">26174152</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M.A., Sundaramoorthy V., Sultana J.M., Yang S., Atkinson R.A.K., Levina V., Halloran M.A., Gleeson P.A., Blair I.P., Soo K.Y., et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 2014;23:3579&#x2013;3595. doi: 10.1093/hmg/ddu068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu068</ArticleId><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki Y., Manzano R., Lee Y., Dafinca R., Aoki M., Douglas A.G.L., Varela M.A., Sathyaprakash C., Scaber J., Barbagallo P., et al. C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2017;140:887&#x2013;897. doi: 10.1093/brain/awx024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx024</ArticleId><ArticleId IdType="pubmed">28334866</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C.P., Smith E.F., Bauer C.S., Moller A., Hautbergue G.M., Ferraiuolo L., Myszczynska M.A., Higginbottom A., Walsh M.J., Whitworth A.J., et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 2016;35:1656&#x2013;1676. doi: 10.15252/embj.201694401.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694401</ArticleId><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J.R., Gregory-Evans C.Y., Shaw C.A. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural. Regen. Res. 2018;13:2050&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume A.G., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., Siwek D.F., Wilcox H.M., Flood D.G., Beal M.F., Brown R.H., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996;13:43&#x2013;47. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson T.D., Deitch J.S., Blankenhorn E.P., Erwin K.L., Perreault M.J., Alexander B.K., Byers N., Toman I., Alexander G.M. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005;236:1&#x2013;7. doi: 10.1016/j.jns.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown R.H., Itoyama Y. Rats Expressing Human Cytosolic Copper&#x2013;Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease. J. Neurosci. 2001;21:9246&#x2013;9254. doi: 10.1523/JNEUROSCI.21-23-09246.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-23-09246.2001</ArticleId><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O.M., Cabrera G.T., Tran H., Gendron T.F., McKeon J.E., Metterville J., Weiss A., Wightman N., Salameh J., Kim J., et al. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015;88:902&#x2013;909. doi: 10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Muhammad A.K.M.G., Gendron T.F., Kim K.J., Austin A., Cady J., Liu E.Y., Zarrow J., Grant S., et al. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015;88:892&#x2013;901. doi: 10.1016/j.neuron.2015.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pattamatta A., Zu T., Reid T., Bardhi O., Borchelt D.R., Yachnis A.T., Ranum L.P.W. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90:521&#x2013;534. doi: 10.1016/j.neuron.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Q., Liang C., Chang Q., Zhang W., Yang M., Chen J.-F. C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner. Acta Neuropathol. Commun. 2019;7:32. doi: 10.1186/s40478-019-0685-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0685-7</ArticleId><ArticleId IdType="pmc">PMC6398253</ArticleId><ArticleId IdType="pubmed">30832726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Vickers T.A., Baker B.F., Bennett C.F., Krainer A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007;5:e73. doi: 10.1371/journal.pbio.0050073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0050073</ArticleId><ArticleId IdType="pmc">PMC1820610</ArticleId><ArticleId IdType="pubmed">17355180</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini M.A., Bu J., Richards A.M., Kinnecom C., Sardi S.P., Stanek L.M., Hua Y., Rigo F., Matson J., Hung G., et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011;3:72ra18. doi: 10.1126/scitranslmed.3001777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001777</ArticleId><ArticleId IdType="pmc">PMC3140425</ArticleId><ArticleId IdType="pubmed">21368223</ArticleId></ArticleIdList></Reference><Reference><Citation>Porensky P.N., Mitrpant C., McGovern V.L., Bevan A.K., Foust K.D., Kaspar B.K., Wilton S.D., Burghes A.H.M. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 2012;21:1625&#x2013;1638. doi: 10.1093/hmg/ddr600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr600</ArticleId><ArticleId IdType="pmc">PMC3298284</ArticleId><ArticleId IdType="pubmed">22186025</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N.K., Singh N.N., Androphy E.J., Singh R.N. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 2006;26:1333&#x2013;1346. doi: 10.1128/MCB.26.4.1333-1346.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.26.4.1333-1346.2006</ArticleId><ArticleId IdType="pmc">PMC1367187</ArticleId><ArticleId IdType="pubmed">16449646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga C.A., Swoboda K.J., Darras B.T., Iannaccone S.T., Montes J., De Vivo D.C., Norris D.A., Bennett C.F., Bishop K.M. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. 2016;86:890&#x2013;897. doi: 10.1212/WNL.0000000000002445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002445</ArticleId><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Chiriboga C.A., Vajsar J., Day J.W., Montes J., De Vivo D.C., Yamashita M., Rigo F., Hung G., Schneider E., et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017&#x2013;3026. doi: 10.1016/S0140-6736(16)31408-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31408-8</ArticleId><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1723&#x2013;1732. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hach&#xe9; M., Swoboda K.J., Sethna N., Farrow-Gillespie A., Khandji A., Xia S., Bishop K.M. Intrathecal Injections in Children with Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience. J. Child. Neurol. 2016;31:899&#x2013;906. doi: 10.1177/0883073815627882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073815627882</ArticleId><ArticleId IdType="pmc">PMC4871174</ArticleId><ArticleId IdType="pubmed">26823478</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E., Darras B.T., Chiriboga C.A., Day J.W., Campbell C., Connolly A.M., Iannaccone S.T., Kirschner J., Kuntz N.L., Saito K., et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2018;378:625&#x2013;635. doi: 10.1056/NEJMoa1710504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Swayze E.E. RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. Annu. Rev. Pharmacol. Toxicol. 2010;50:259&#x2013;293. doi: 10.1146/annurev.pharmtox.010909.105654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.010909.105654</ArticleId><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A., Cole T., Wegener A.J., Tomassy G.S., Setnicka A., Farley B.J., Schoch K.M., Hoye M.L., Shabsovich M., Sun L., et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clinic. Investig. 2018;128:3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.-W., Pham J.T., Heusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.-R., Jiang J., Watt A.T., Chun S., Katz M., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., O&#x2019;Rourke J.G., Meera P., Muhammad A.K.M.G., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A., et al. Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion. Sci. Transl. Med. 2013;5:208ra149. doi: 10.1126/scitranslmed.3007529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A.J., Sendtner M., Shaw P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431:343&#x2013;349. doi: 10.1038/nature02873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02873</ArticleId><ArticleId IdType="pubmed">15372041</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature. 2004;431:371&#x2013;378. doi: 10.1038/nature02870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02870</ArticleId><ArticleId IdType="pubmed">15372045</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjunath N., Haoquan W., Sandesh S., Premlata S. Lentiviral delivery of short hairpin RNAs. Adv. Drug. Deliv. Rev. 2009;61:732&#x2013;745. doi: 10.1016/j.addr.2009.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2009.03.004</ArticleId><ArticleId IdType="pmc">PMC2789654</ArticleId><ArticleId IdType="pubmed">19341774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel D.P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004;116:281&#x2013;297. doi: 10.1016/S0092-8674(04)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00045-5</ArticleId><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H., Schwarz D.S., Keene A., Affar E.B., Fenton L., Xia X., Shi Y., Zamore P.D., Xu Z. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell. 2003;2:209&#x2013;217. doi: 10.1046/j.1474-9728.2003.00054.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1474-9728.2003.00054.x</ArticleId><ArticleId IdType="pubmed">12934714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvanov A.A., Mukhamedyarov M.A., Palot&#xe1;s A., Islamov R.R. Retrogradely transported siRNA silences human mutant SOD1 in spinal cord motor neurons. Exp. Brain Res. 2009;195:1&#x2013;4. doi: 10.1007/s00221-009-1742-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-009-1742-4</ArticleId><ArticleId IdType="pubmed">19259649</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleavey G.F., Watts J.K., Damha M.J. Chemical Modification of siRNA. In: Beaucage S.L., Bergstrom D.E., Herdewijn P., Matsuda A., editors. Current Protocols in Nucleic Acid Chemistry. John Wiley &amp; Sons, Inc.; Hoboken, NJ, USA: 2009. pp. 16.3.1&#x2013;16.3.22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20013783</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Wang C.C., Choy K.W., Du Q., Chen J., Wang Q., Li L., Chung T.K.H., Tang T. Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene. 2014;538:217&#x2013;227. doi: 10.1016/j.gene.2013.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2013.12.019</ArticleId><ArticleId IdType="pubmed">24406620</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D.R., Pulst S.M. Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biol. 2018;15:707&#x2013;714. doi: 10.1080/15476286.2018.1454812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2018.1454812</ArticleId><ArticleId IdType="pmc">PMC6152438</ArticleId><ArticleId IdType="pubmed">29560813</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash S., Malhotra M., Rengaswamy V. Nonviral siRNA delivery for gene silencing in neurodegenerative diseases. Method. Mol. Biol. 2010;623:211&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">20217554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond S.M., Hazell G., Shabanpoor F., Saleh A.F., Bowerman M., Sleigh J.N., Meijboom K.E., Zhou H., Muntoni F., Talbot K., et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA. 2016;27:10962&#x2013;10967. doi: 10.1073/pnas.1605731113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605731113</ArticleId><ArticleId IdType="pmc">PMC5047168</ArticleId><ArticleId IdType="pubmed">27621445</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M. Gene Therapy for ALS: Progress and prospects. Biochim. Biophys. Acta Mol. Basis Dis. 2006;1762:1122&#x2013;1127. doi: 10.1016/j.bbadis.2006.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.003</ArticleId><ArticleId IdType="pubmed">16806843</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessing D., D&#xe9;glon N. Adeno-associated virus and lentivirus vectors: A refined toolkit for the central nervous system. Curr. Opin. Virol. 2016;21:61&#x2013;66. doi: 10.1016/j.coviro.2016.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.08.004</ArticleId><ArticleId IdType="pubmed">27559630</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson B.L., Breakefield X.O. Viral vectors for gene delivery to the nervous system. Nat. Rev. Neurosci. 2003;4:353&#x2013;364. doi: 10.1038/nrn1104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1104</ArticleId><ArticleId IdType="pubmed">12728263</ArticleId></ArticleIdList></Reference><Reference><Citation>Escors D., Breckpot K. Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential. Arch. Immunol. Ther. Exp. 2010;58:107&#x2013;119. doi: 10.1007/s00005-010-0063-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-010-0063-4</ArticleId><ArticleId IdType="pmc">PMC2837622</ArticleId><ArticleId IdType="pubmed">20143172</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003;4:346&#x2013;358. doi: 10.1038/nrg1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg1066</ArticleId><ArticleId IdType="pubmed">12728277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsson J., Lundberg C. Lentiviral Vectors for Use in the Central Nervous System. Mol. Ther. 2006;13:484&#x2013;493. doi: 10.1016/j.ymthe.2005.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2005.11.012</ArticleId><ArticleId IdType="pubmed">16403676</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldini L., Bl&#xf6;mer U., Gage F.H., Trono D., Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA. 1996;93:11382&#x2013;11388. doi: 10.1073/pnas.93.21.11382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.21.11382</ArticleId><ArticleId IdType="pmc">PMC38066</ArticleId><ArticleId IdType="pubmed">8876144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hislop J.N., Islam T.A., Eleftheriadou I., Carpentier D.C.J., Trabalza A., Parkinson M., Schiavo G., Mazarakis N.D. Rabies Virus Envelope Glycoprotein Targets Lentiviral Vectors to the Axonal Retrograde Pathway in Motor Neurons. J. Biol. Chem. 2014;289:16148&#x2013;16163. doi: 10.1074/jbc.M114.549980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.549980</ArticleId><ArticleId IdType="pmc">PMC4047386</ArticleId><ArticleId IdType="pubmed">24753246</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabalza A., Eleftheriadou I., Sgourou A., Liao T.-Y., Patsali P., Lee H., Mazarakis N.D. Enhanced Central Nervous System Transduction with Lentiviral Vectors Pseudotyped with RVG/HIV-1gp41 Chimeric Envelope Glycoproteins. J. Virol. 2014;88:2877&#x2013;2890. doi: 10.1128/JVI.03376-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03376-13</ArticleId><ArticleId IdType="pmc">PMC3958067</ArticleId><ArticleId IdType="pubmed">24371049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Kato S., Kobayashi K. Genetic manipulation of specific neural circuits by use of a viral vector system. J. Neural. Transm. 2018;125:67&#x2013;75. doi: 10.1007/s00702-016-1674-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-016-1674-7</ArticleId><ArticleId IdType="pubmed">28058503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano M., Kato S., Kobayashi K., Okada T., Yaginuma H., Kobayashi K. Highly Efficient Retrograde Gene Transfer into Motor Neurons by a Lentiviral Vector Pseudotyped with Fusion Glycoprotein. PLoS ONE. 2013;8:e75896. doi: 10.1371/journal.pone.0075896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075896</ArticleId><ArticleId IdType="pmc">PMC3782444</ArticleId><ArticleId IdType="pubmed">24086660</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Julien J.-P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013;14:161&#x2013;176. doi: 10.1038/nrn3380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3380</ArticleId><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C., Abbas-Terki T., Bensadoun J.-C., Guillot S., Haase G., Szulc J., Henderson C.E., Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 2005;11:423&#x2013;428. doi: 10.1038/nm1207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1207</ArticleId><ArticleId IdType="pubmed">15768028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C.P., Wong L.-F., Bilsland L.G., Greensmith L., Kingsman S.M., et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 2005;11:429&#x2013;433. doi: 10.1038/nm1205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1205</ArticleId><ArticleId IdType="pubmed">15768029</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury S.R., Hudry E., Maguire C.A., Sena-Esteves M., Breakefield X.O., Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. 2017;120:63&#x2013;80. doi: 10.1016/j.neuropharm.2016.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.02.013</ArticleId><ArticleId IdType="pmc">PMC5929167</ArticleId><ArticleId IdType="pubmed">26905292</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Svendsen C.N. Ex Vivo Gene Therapy Using Human Mesenchymal Stem Cells to Deliver Growth Factors in the Skeletal Muscle of a Familial ALS Rat Model. Method. Mol. Biol. 2016;1382:325&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">26611598</ArticleId></ArticleIdList></Reference><Reference><Citation>Samulski R.J., Muzyczka N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu. Rev. Virol. 2014;1:427&#x2013;451. doi: 10.1146/annurev-virology-031413-085355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-031413-085355</ArticleId><ArticleId IdType="pubmed">26958729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi F., High K.A. Immune responses to AAV in clinical trials. Curr. Gene Ther. 2007;7:316&#x2013;324. doi: 10.2174/156652307782151425.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652307782151425</ArticleId><ArticleId IdType="pubmed">17979678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaiss A.K., Muruve D.A. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 2005;5:323&#x2013;331. doi: 10.2174/1566523054065039.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566523054065039</ArticleId><ArticleId IdType="pubmed">15975009</ArticleId></ArticleIdList></Reference><Reference><Citation>Asokan A., Schaffer D.V., Samulski R.J. The AAV vector toolkit: Poised at the clinical crossroads. Mol. Ther. 2012;20:699&#x2013;708. doi: 10.1038/mt.2011.287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.287</ArticleId><ArticleId IdType="pmc">PMC3321598</ArticleId><ArticleId IdType="pubmed">22273577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hester M., Foust K., Kaspar R., Kaspar B. AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS. Curr. Gene Ther. 2009;9:428&#x2013;433. doi: 10.2174/156652309789753383.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652309789753383</ArticleId><ArticleId IdType="pubmed">19860657</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman B.E., Ravina B.M., Bankiewicz K.S., Paul S.M., Sah D.W.Y. Gene therapy for neurological disorders: Progress and prospects. Nat. Rev. Drug Discov. 2018;17:641&#x2013;659. doi: 10.1038/nrd.2018.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.110</ArticleId><ArticleId IdType="pubmed">30093643</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.-M., Fyfe J., Moullier P., Colle M.-A., Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009;17:1187&#x2013;1196. doi: 10.1038/mt.2009.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.71</ArticleId><ArticleId IdType="pmc">PMC2835208</ArticleId><ArticleId IdType="pubmed">19367261</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., Le T.T., Morales P.R., Rich M.M., Burghes A.H.M., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 2010;28:271&#x2013;274. doi: 10.1038/nbt.1610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1610</ArticleId><ArticleId IdType="pmc">PMC2889698</ArticleId><ArticleId IdType="pubmed">20190738</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanguy Y., Biferi M.G., Besse A., Astord S., Cohen-Tannoudji M., Marais T., Barkats M. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front. Mol. Neurosci. 2015;8:36. doi: 10.3389/fnmol.2015.00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2015.00036</ArticleId><ArticleId IdType="pmc">PMC4516891</ArticleId><ArticleId IdType="pubmed">26283910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G., Alvira M.R., Somanathan S., Lu Y., Vandenberghe L.H., Rux J.J., Calcedo R., Sanmiguel J., Abbas Z., Wilson J.M. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. USA. 2003;100:6081&#x2013;6086. doi: 10.1073/pnas.0937739100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0937739100</ArticleId><ArticleId IdType="pmc">PMC156329</ArticleId><ArticleId IdType="pubmed">12716974</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G.-P., Alvira M.R., Wang L., Calcedo R., Johnston J., Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA. 2002;99:11854&#x2013;11859. doi: 10.1073/pnas.182412299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.182412299</ArticleId><ArticleId IdType="pmc">PMC129358</ArticleId><ArticleId IdType="pubmed">12192090</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevtsova Z., Malik J.M.I., Michel U., B&#xe4;hr M., K&#xfc;gler S. Promoters and serotypes: Targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp. Physiol. 2005;90:53&#x2013;59. doi: 10.1113/expphysiol.2004.028159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/expphysiol.2004.028159</ArticleId><ArticleId IdType="pubmed">15542619</ArticleId></ArticleIdList></Reference><Reference><Citation>von Jonquieres G., Mersmann N., Klugmann C.B., Harasta A.E., Lutz B., Teahan O., Housley G.D., Fr&#xf6;hlich D., Kr&#xe4;mer-Albers E.-M., Klugmann M. Glial Promoter Selectivity following AAV-Delivery to the Immature Brain. PLoS ONE. 2013;8:e65646. doi: 10.1371/journal.pone.0065646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065646</ArticleId><ArticleId IdType="pmc">PMC3683058</ArticleId><ArticleId IdType="pubmed">23799030</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle M.J., Perlson E., Holzbaur E.L., Wolfe J.H. Long-distance Axonal Transport of AAV9 Is Driven by Dynein and Kinesin-2 and Is Trafficked in a Highly Motile Rab7-positive Compartment. Mol. Ther. 2014;22:554&#x2013;566. doi: 10.1038/mt.2013.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.237</ArticleId><ArticleId IdType="pmc">PMC3944332</ArticleId><ArticleId IdType="pubmed">24100640</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty D.M. Self-complementary AAV Vectors; Advances and Applications. Mol. Ther. 2008;16:1648&#x2013;1656. doi: 10.1038/mt.2008.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.171</ArticleId><ArticleId IdType="pubmed">18682697</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal-neurons and adult-astrocytes in CNS. Nat. Biotechnol. 2009;27:59&#x2013;65. doi: 10.1038/nbt.1515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId><ArticleId IdType="pmc">PMC2895694</ArticleId><ArticleId IdType="pubmed">19098898</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez E., Marais T., Chatauret N., Benkhelifa-Ziyyat S., Duque S., Ravassard P., Carcenac R., Astord S., Pereira de Moura A., Voit T., et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 2011;20:681&#x2013;693. doi: 10.1093/hmg/ddq514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq514</ArticleId><ArticleId IdType="pubmed">21118896</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori C.F., Ning K., Wyles M., Mead R.J., Grierson A.J., Shaw P.J., Azzouz M. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2010;2:35ra42. doi: 10.1126/scitranslmed.3000830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000830</ArticleId><ArticleId IdType="pubmed">20538619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1713&#x2013;1722. doi: 10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Salazar D.L., Likhite S., Ferraiuolo L., Ditsworth D., Ilieva H., Meyer K., Schmelzer L., Braun L., Cleveland D.W., et al. Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol. Ther. 2013;21:2148&#x2013;2159. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T., Scarrott J.M., Likhite S., Coldicott I.R.P., Lewis K.E., Heath P.R., Higginbottom A., Myszczynska M.A., Milo M., Hautbergue G.M., et al. Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Mol. Ther. Nucleic Acids. 2018;12:75&#x2013;88. doi: 10.1016/j.omtn.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yang B., Qiu L., Yang C., Kramer J., Su Q., Guo Y., Brown R.H., Gao G., Xu Z. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014;23:668&#x2013;681. doi: 10.1093/hmg/ddt454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt454</ArticleId><ArticleId IdType="pmc">PMC3888258</ArticleId><ArticleId IdType="pubmed">24108104</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Toro Cabreja G.C., Song L., Su Q., Gao G.P., Elmallah M.K., Brown R.H., et al. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates. Hum. Gene Ther. 2016;27:19&#x2013;31. doi: 10.1089/hum.2015.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10:eaau6414. doi: 10.1126/scitranslmed.aau6414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A.J., Norrbom M., Chun S., Bennett C.F., Rigo F. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Nucleic Acids Res. 2014;42:5871&#x2013;5879. doi: 10.1093/nar/gku184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku184</ArticleId><ArticleId IdType="pmc">PMC4027159</ArticleId><ArticleId IdType="pubmed">24589581</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi M.G., Cohen-Tannoudji M., Cappelletto A., Giroux B., Roda M., Astord S., Marais T., Bos C., Voit T., Ferry A., et al. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol. Ther. 2017;25:2038&#x2013;2052. doi: 10.1016/j.ymthe.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;mperli D., Pillai R.S. The special Sm core structure of the U7 snRNP: Far-reaching significance of a small nuclear ribonucleoprotein. Cell. Mol. Life Sci. 2004;61:2560&#x2013;2570. doi: 10.1007/s00018-004-4190-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-004-4190-0</ArticleId><ArticleId IdType="pubmed">15526162</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Garc&#xed;a-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids. 2019;16:26&#x2013;37. doi: 10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic Acids. 2019;14:593&#x2013;608. doi: 10.1016/j.omtn.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L., Fisher A.L., Huang H., Xie Z. CRISPR-mediated genome editing and human diseases. Genes Dis. 2016;3:244&#x2013;251. doi: 10.1016/j.gendis.2016.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2016.07.003</ArticleId><ArticleId IdType="pmc">PMC6150104</ArticleId><ArticleId IdType="pubmed">30258895</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823. doi: 10.1126/science.1231143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1231143</ArticleId><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science. 2013;339:823&#x2013;826. doi: 10.1126/science.1232033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232033</ArticleId><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;821. doi: 10.1126/science.1225829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1225829</ArticleId><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3:eaar3952. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Pribadi M., Yang Z., Kim T.S., Swartz E.W., Huang A.Y., Chen J.A., Dokuru D., Baek J., Gao F., Fua A.T., et al. CRISPR-Cas9 targeted deletion of the C9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived iPS cells. bioRxiv. 2016:051193. doi: 10.1101/051193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/051193</ArticleId></ArticleIdList></Reference><Reference><Citation>McEachin Z.T., Donsante A., Boulis N. Gene Therapy for the Treatment of Neurological Disorders: Amyotrophic Lateral Sclerosis. In: Manfredsson F.P., editor. Gene Therapy for Neurological Disorders. Volume 1382. Springer New York; New York, NY, USA: 2016. pp. 399&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">26611602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L.-J., Lu Y.-Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 2002;22:6920&#x2013;6928. doi: 10.1523/JNEUROSCI.22-16-06920.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-16-06920.2002</ArticleId><ArticleId IdType="pmc">PMC6757879</ArticleId><ArticleId IdType="pubmed">12177190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar B.K., Llad&#xf3; J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model. Science. 2003;301:839&#x2013;842. doi: 10.1126/science.1086137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086137</ArticleId><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413. doi: 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007;1185:256&#x2013;265. doi: 10.1016/j.brainres.2007.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.034</ArticleId><ArticleId IdType="pmc">PMC2265207</ArticleId><ArticleId IdType="pubmed">17963733</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz C.K., Federici T., Yang J., Backus C., Oh S.S., Teng Q., Carlton E., Bishop K.M., Gasmi M., Bartus R.T., et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol. Dis. 2009;33:473&#x2013;481. doi: 10.1016/j.nbd.2008.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.12.003</ArticleId><ArticleId IdType="pubmed">19135533</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 2008;16:1056&#x2013;1064. doi: 10.1038/mt.2008.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.60</ArticleId><ArticleId IdType="pmc">PMC2737251</ArticleId><ArticleId IdType="pubmed">18388910</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., Rao M., Eagle A., Matthews J.C., Taksir T.V., et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 2010;18:2075&#x2013;2084. doi: 10.1038/mt.2010.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.206</ArticleId><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowerman M., Becker C.G., Y&#xe1;&#xf1;ez-Mu&#xf1;oz R.J., Ning K., Wood M.J.A., Gillingwater T.H., Talbot K., Consortium T.U.S.R. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis. Model. Mech. 2017;10:943&#x2013;954. doi: 10.1242/dmm.030148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.030148</ArticleId><ArticleId IdType="pmc">PMC5560066</ArticleId><ArticleId IdType="pubmed">28768735</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkler C., Barhum Y., Ben-Zur T., Offen D. Multifactorial Gene Therapy Enhancing the Glutamate Uptake System and Reducing Oxidative Stress Delays Symptom Onset and Prolongs Survival in the SOD1-G93A ALS Mouse Model. J. Mol. Neurosci. 2016;58:46&#x2013;58. doi: 10.1007/s12031-015-0695-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-015-0695-2</ArticleId><ArticleId IdType="pubmed">26691332</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A.E., Braun L., Ferraiuolo L., Guttridge D.C., Kaspar B.K. Additive amelioration of ALS by co-targeting independent pathogenic mechanisms. Ann. Clinic. Transl. Neurol. 2017;4:76&#x2013;86. doi: 10.1002/acn3.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.375</ArticleId><ArticleId IdType="pmc">PMC5288461</ArticleId><ArticleId IdType="pubmed">28168207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>